CALML5

Across TCGA pan-cancer cohorts, CALML5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CALML5 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CALML5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CALML5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

LUAD, UCEC, and GBM are the cancer types where CALML5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.808	0.926	.008	4	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.327	.004	4	view →
GBM	DFS	Median	All	0.458	0.268	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CALML5–LUAD (DFS)

Open the LUAD breakdown →